Province expanding access to Paxlovid for COVID-19 patients22 September 2022
FREDERICTON (GNB) – Access to Paxlovid treatments has been expanded in the province to include anyone who has recently tested positive for COVID-19, is experiencing mild to moderate symptoms, and is at risk of severe outcomes from the virus.
Paxlovid is the first oral antiviral treatment for COVID-19 approved by Health Canada.
People may be at higher risk of severe outcomes if they are immunocompromised, have chronic medical conditions or are a senior.
Pharmacists can now do assessments and prescribe the antiviral.
Previously, New Brunswickers had to see a physician or nurse practitioner within five days of the onset of symptoms to find out if they were eligible for the treatments. The change is intended to make it easier for eligible patients to access this option.
The change follows a collaboration with the New Brunswick College of Pharmacists and the New Brunswick Pharmacists’ Association to establish a new assessment and prescribing option for the treatment.
A list of participating pharmacies is available online.